Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 1/20 | 0.43 |
| ▸ | DYRK1A | Q13627 | 7/20 | 0.42 |
| ▸ | CNR1 | P21554 | 1/20 | 0.40 |
| ▸ | CDK9 | P50750 | 1/20 | 0.40 |
| ▸ | PLAU | P00749 | 1/20 | 0.39 |
| ▸ | KMO | O15229 | 1/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 2/20 | 0.38 |
| ▸ | FABP3 | P05413 | 1/20 | 0.37 |
| ▸ | FABP4 | P15090 | 1/20 | 0.37 |
| ▸ | FABP5 | Q01469 | 1/20 | 0.37 |
| ▸ | AURKA | O14965 | 1/20 | 0.37 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.37 |
| ▸ | CDC7 | O00311 | 1/20 | 0.37 |
| ▸ | FOXO1 | Q12778 | 1/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | BTK | Q06187 | 1/20 | 0.36 |
| ▸ | HTR1B | P28222 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1826481 | 0.83 | DYRK1A (0.46) | ARDYRK1ACNR1CDK9PLAU | |
| SCHEMBL219746 | 0.79 | CDC7 (0.48) | BRD4CDC7 | |
| SCHEMBL12423887 | 0.77 | BRD4 (0.59) | BRD4CDC7 | |
| SCHEMBL2200146 | 0.77 | BRD4 (0.62) | CDK9BRD4CDC7 | |
| SCHEMBL220935 | 0.76 | CDC7 (0.51) | DYRK1ABRD4CA2CDC7CA12 | |
| SCHEMBL2201619 | 0.76 | BRD4 (0.45) | BRD4CDC7 | |
| SCHEMBL12424010 | 0.75 | PTGER2 (0.42) | BRD4CDC7 | |
| SCHEMBL2200000 | 0.75 | IKBKB (0.51) | BRD4CDC7 | |
| SCHEMBL2200813 | 0.75 | ABL1 (0.40) | BRD4CDC7 | |
| SCHEMBL2203027 | 0.75 | IDO1 (0.43) | BRD4CDC7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | claimed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | claimed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-8088817-B2 | Pyrrole derivative having, as substituents, ureido group, aminocarbonly group and bicyclic group which may have substituent | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2012-01-03 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | SANTEN PHARMACEUTICAL CO., LTD. (JP) | 2011-06-09 | — | — | US | disclosed |
| EP-2319831-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDE GROUP, AMINOCARBONYL GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | Santen Pharmaceutical Co., Ltd (JP) | 2011-05-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110136794-A1 | NOVEL PYRROLE DERIVATIVE HAVING, AS SUBSTITUENTS, UREIDO GROUP, AMINOCARBONLY GROUP AND BICYCLIC GROUP WHICH MAY HAVE SUBSTITUENT | IL6, IL6ST, UACA | AR 2351/4885DYRK1A 4841/4885CNR1 258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.